North America And Europe Minimally Invasive Prostate Cancer Surgery Market is estimated to be valued at USD 74.03 Bn in 2026 and is expected to reach USD 165.71 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.2% from 2026 to 2033.
| Report Coverage |
Report Details |
| Base Year: |
2025 |
Market Size in 2026: |
USD 74.03 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: |
12.20% |
2033 Value Projection: |
USD 165.71 Bn |
Prostate cancer is associated with high mortality among men. The major factors increasing the risk of the disease constitute of old age, heredity, and lifestyle aspects such as smoking and diet rich in red meat. Cancer Digital Rectal Exam (DRE), prostate biopsy, Prostate Specific Antigen (PSA) blood test, bone scan, ultrasound, computed tomography (CT) scan, magnetic resonance imaging (MRI), lymph node biopsy, and ProstaScint monoclonal antibody scan are generally used for the diagnosis of prostate cancer. Laparoscopy, cryosurgery, brachytherapy, and robotic surgery are the common practices surgical techniques while performing minimally invasive surgeries for the treatment of prostate cancer. Factors, such as the increasing prevalence of prostate cancer, increasing product approvals, and increasing investments in research and development, are expected to propel the market growth during the forecast period.
Market Dynamics
Increasing product approvals by regulatory authorities are expected to drive the North America and Europe minimally invasive prostate cancer surgery market growth over the forecast period. For instance, in May 2021, Avenda Health, a health technology company, announced the U.S. Food and Drug Administration (FDA) approval device designation for technology to treat prostate cancer, aiming to improve cancer outcomes through Artificial Intelligence (AI) and minimally invasive technologies. The Avenda Health Focal Therapy System, which is designed to spare healthy tissues and minimize side effects, uses patient-specific information and artificial intelligence (AI) to deliver a precise and personalized treatment, targeting only the tumor. This treatment can be performed in a physician's office with just local anesthesia, minimizing the patient's downtime and potentially reducing cost to the healthcare system.
Key features of the study:
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the North America and Europe minimally invasive prostate cancer surgery market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as a part of this study include AngioDynamics, Profound Medical, Medtronic, Johnson & Johnson Services, Inc., Olympus, Siemens Healthcare, Intuitive Surgical Operations, Inc., B. Braun SE, Delta Healthcare, ESC Medicams, Zhejiang Geyi Medical Instrument Co., Ltd., XION, Fulbright Medical Inc., and CONMED Corporation
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics
- The North America and Europe minimally invasive prostate cancer surgery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America and Europe minimally invasive prostate cancer surgery market
Detailed Segmentation:
- North America and Europe Minimally Invasive Prostate Cancer Surgery Market, Product Type (Revenue, USD Bn, 2021 - 2033)
- Hand
- Resectoscope
- Linear Cutter
- Insufflators
- Curved Stapler
- Endoscopic Trocars
- Prostatic Retractor
- Cryoablation Device
- Others
- Monitoring & Visualization
- Cameras & Video Support
- Endoscopic Trocars with Optical View
- Powered
- Electrosurgical Unit
- Lasers
- North America and Europe Minimally Invasive Prostate Cancer Surgery Market, By Application (Revenue, USD Bn, 2021 - 2033)
- Laparoscopy
- Robotics
- Brachytherapy
- Cryosurgery
- North America and Europe Minimally Invasive Prostate Cancer Surgery Market, By End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- North America and Europe Minimally Invasive Prostate Cancer Surgery Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Company Profiles
- AngioDynamics
- Profound Medical
- Medtronic
- Johnson & Johnson Services, Inc.
- Olympus, Siemens Healthcare
- Intuitive Surgical Operations, Inc.
- Braun SE
- Delta Healthcare
- ESC Medicams
- Zhejiang Geyi Medical Instrument Co.,Ltd
- XION
- Fulbright Medical Inc.
- CONMED Corporation